T 1041/23 (Dapagliflozin formulations / ASTRAZENECA) of 10.04.2025
- European Case Law Identifier
- ECLI:EP:BA:2025:T104123.20250410
- Date of decision
- 10 April 2025
- Case number
- T 1041/23
- Petition for review of
- -
- Application number
- 08732695.5
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- PHARMACEUTICAL FORMULATIONS CONTAINING DAPAGLIFLOZIN PROPYLENE GLYCOL HYDRATE
- Applicant name
- AstraZeneca AB
- Opponent name
- Zentiva, k.s.
Galenicum Health S.L.U.
Generics [UK] Limited
Stada-Arzneimittel Aktiengesellschaft
Gedeon Richter Plc.
Kraus & Lederer PartGmbB - Board
- 3.3.07
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 104(1)European Patent Convention Art 113(1)European Patent Convention R 103(1)(a)Rules of procedure of the Boards of Appeal 2020 Art 011Rules of procedure of the Boards of Appeal Art 16(1)
- Keywords
- Substantial procedural violation - violation of the right to be heard (yes)
Remittal to the department of first instance
Remittal - fundamental deficiency in first instance proceedings (yes)
Reimbursement of appeal fee - equitable by reason of a substantial procedural violation (yes)
Apportionment of costs - not equitable - Catchword
- -
- Cited cases
- G 0001/92
- Citing cases
- -
Order
For these reasons it is decided that:
The decision under appeal is set aside.
The case is remitted to the opposition division for further prosecution.
The appeal fee is to be reimbursed.
The request for a different apportionment of costs is rejected.